NASDAQ:CHRS Coherus BioSciences (CHRS) Stock Forecast, Price & News $4.46 +0.32 (+7.73%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$4.14▼$4.4850-Day Range$4.14▼$5.4552-Week Range$3.60▼$10.99Volume2.71 million shsAverage Volume3.56 million shsMarket Capitalization$421.34 millionP/E RatioN/ADividend YieldN/APrice Target$14.63 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Coherus BioSciences MarketRank™ ForecastAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside227.9% Upside$14.63 Price TargetShort InterestBearish16.57% of Shares Sold ShortDividend StrengthN/ASustainability-1.08Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.97) to $0.03 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.33 out of 5 starsMedical Sector333rd out of 963 stocksBiological Products, Except Diagnostic Industry51st out of 158 stocks 3.4 Analyst's Opinion Consensus RatingCoherus BioSciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.63, Coherus BioSciences has a forecasted upside of 227.9% from its current price of $4.46.Amount of Analyst CoverageCoherus BioSciences has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted16.57% of the outstanding shares of Coherus BioSciences have been sold short.Short Interest Ratio / Days to CoverCoherus BioSciences has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Coherus BioSciences has recently decreased by 0.32%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCoherus BioSciences does not currently pay a dividend.Dividend GrowthCoherus BioSciences does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCoherus BioSciences has received a 69.63% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Pegfilgrastim", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Coherus BioSciences is -1.08. Previous Next 2.8 News and Social Media Coverage News SentimentCoherus BioSciences has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Coherus BioSciences this week, compared to 2 articles on an average week.Search Interest6 people have searched for CHRS on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Coherus BioSciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -78% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Coherus BioSciences insiders have not sold or bought any company stock.Percentage Held by Insiders10.99% of the stock of Coherus BioSciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.86% of the stock of Coherus BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Coherus BioSciences are expected to grow in the coming year, from ($1.97) to $0.03 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Coherus BioSciences is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Coherus BioSciences is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Coherus BioSciences (NASDAQ:CHRS) StockCoherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the United States. It also offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; and Shanghai Junshi Biosciences Co., Ltd. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Read More CHRS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CHRS Stock News HeadlinesSeptember 24, 2023 | americanbankingnews.comCoherus BioSciences, Inc. (NASDAQ:CHRS) Given Average Recommendation of "Moderate Buy" by AnalystsSeptember 15, 2023 | finance.yahoo.comWith 72% institutional ownership, Coherus BioSciences, Inc. (NASDAQ:CHRS) is a favorite amongst the big gunsSeptember 24, 2023 | Legacy Research (Ad)WARNING: Mandatory U.S. Dollar Recall is Weeks AwayIf you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.September 8, 2023 | msn.comWhy Coherus BioSciences Stock Was Plunging This WeekSeptember 1, 2023 | finance.yahoo.comCoherus BioSciences to Participate at Upcoming September Investor ConferencesSeptember 1, 2023 | finance.yahoo.comCoherus BioSciences to Participate at Upcoming September Investor ConferencesAugust 31, 2023 | finance.yahoo.comSurface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciencesAugust 15, 2023 | msn.comSurface Oncology And Coherus BioSciences: Does A Buyout Equal A Good Deal?September 24, 2023 | Legacy Research (Ad)WARNING: Mandatory U.S. Dollar Recall is Weeks AwayIf you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.August 3, 2023 | markets.businessinsider.comAnalyst Ratings for Coherus BioSciencesAugust 3, 2023 | finance.yahoo.comCoherus BioSciences Reports Second Quarter 2023 Financial Results and Business HighlightsAugust 3, 2023 | seekingalpha.comCoherus BioSciences, Inc. (CHRS) Q2 2023 Earnings Call TranscriptJuly 26, 2023 | finance.yahoo.comCoherus BioSciences to Report Second Quarter 2023 Financial Results on August 02, 2023July 24, 2023 | msn.comCitigroup Initiates Coverage of Coherus Biosciences (CHRS) with Buy RecommendationJuly 23, 2023 | seekingalpha.comCoherus: 'Hold' As Biosimilar Growth Initiatives Play OutJuly 20, 2023 | finance.yahoo.comCoherus BioSciences Appoints Dr. Michael Ryan to its Board of DirectorsJuly 14, 2023 | markets.businessinsider.com10 Analysts Have This to Say About Coherus BioSciencesJuly 14, 2023 | msn.comTruist Securities Maintains Coherus Biosciences (CHRS) Buy RecommendationJuly 13, 2023 | finance.yahoo.comCoherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY™July 6, 2023 | msn.comCoherus Biosciences (CHRS) Price Target Decreased by 8.39% to 14.72July 6, 2023 | seekingalpha.comCoherus: Why I Am Exiting, But Also Why You May Want To Hold OnJuly 3, 2023 | markets.businessinsider.comCoherus Rolls Out YUSIMRY At $995 Per Carton In USJuly 3, 2023 | finance.yahoo.comUPDATE 1-Coherus BioSciences launches biosimilar version of AbbVie's blockbuster HumiraJune 29, 2023 | msn.comTruist Securities Reiterates Coherus Biosciences (CHRS) Buy RecommendationJune 27, 2023 | markets.businessinsider.comCredit Suisse Remains a Buy on Coherus Biosciences (CHRS)June 20, 2023 | markets.businessinsider.comSynergy Of Coherus And Surface Oncology: Analyst Forecasts $50M Savings And 2024 ProfitabilityJune 20, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for Coherus Biosciences (CHRS)See More Headlines Receive CHRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CHRS Company Calendar Last Earnings8/02/2023Today9/24/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CHRS CUSIPN/A CIK1512762 Webwww.coherus.com Phone(650) 649-3530FaxN/AEmployees294Year Founded2010Price Target and Rating Average Stock Price Forecast$14.63 High Stock Price Forecast$23.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+227.9%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-291,750,000.00 Net Margins-145.18% Pretax Margin-145.18% Return on EquityN/A Return on Assets-54.47% Debt Debt-to-Equity RatioN/A Current Ratio2.28 Quick Ratio1.90 Sales & Book Value Annual Sales$211.04 million Price / Sales2.00 Cash FlowN/A Price / Cash FlowN/A Book Value($1.77) per share Price / Book-2.52Miscellaneous Outstanding Shares94,470,000Free Float84,086,000Market Cap$421.34 million OptionableOptionable Beta0.88 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Dennis M. Lanfear (Age 68)Chairman, Pres & CEO Comp: $1.79MMr. McDavid Stilwell (Age 51)Chief Financial Officer Comp: $719.64kMr. Bryan J. Mcmichael (Age 45)Sr. VP of Accounting, Principal Accounting Officer & Corp. Controller Mr. Richard L. HameisterChief Technical OfficerMr. Marek Ciszewski J.D.Sr. VP of Investor RelationsMr. Christopher W. Slavinsky (Age 50)Chief Bus. & Legal Officer Cheston TurbyfillVP of CommunicationsMs. Rebecca Sunshine (Age 60)Chief HR Officer Mr. Michael ChenSr. VP of Commercial Analytics & TradeMr. Paul Reider (Age 54)Chief Commercial Officer More ExecutivesKey CompetitorsiTeos TherapeuticsNASDAQ:ITOSCullinan OncologyNASDAQ:CGEMIcosavaxNASDAQ:ICVXAgenusNASDAQ:AGENScholar RockNASDAQ:SRRKView All CompetitorsInstitutional OwnershipWolverine Trading LLCBought 19,700 shares on 8/23/2023Ownership: 0.000%California State Teachers Retirement SystemBought 16,638 shares on 8/21/2023Ownership: 0.104%Scout Investments Inc.Sold 18,814 shares on 8/15/2023Ownership: 0.669%State of Tennessee Treasury DepartmentBought 7,925 shares on 8/15/2023Ownership: 0.049%Boothbay Fund Management LLCBought 15,000 shares on 8/15/2023Ownership: 0.016%View All Institutional Transactions CHRS Stock - Frequently Asked Questions Should I buy or sell Coherus BioSciences stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CHRS shares. View CHRS analyst ratings or view top-rated stocks. What is Coherus BioSciences' stock price forecast for 2023? 7 equities research analysts have issued twelve-month price objectives for Coherus BioSciences' stock. Their CHRS share price forecasts range from $8.00 to $23.00. On average, they expect the company's stock price to reach $14.63 in the next twelve months. This suggests a possible upside of 227.9% from the stock's current price. View analysts price targets for CHRS or view top-rated stocks among Wall Street analysts. How have CHRS shares performed in 2023? Coherus BioSciences' stock was trading at $7.92 at the start of the year. Since then, CHRS stock has decreased by 43.7% and is now trading at $4.46. View the best growth stocks for 2023 here. When is Coherus BioSciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our CHRS earnings forecast. How were Coherus BioSciences' earnings last quarter? Coherus BioSciences, Inc. (NASDAQ:CHRS) announced its quarterly earnings data on Wednesday, August, 2nd. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.66) by $0.17. The biotechnology company had revenue of $58.72 million for the quarter, compared to analyst estimates of $50.83 million. What ETFs hold Coherus BioSciences' stock? ETFs with the largest weight of Coherus BioSciences (NASDAQ:CHRS) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA).First Trust Innovation Leaders ETF (ILDR). What guidance has Coherus BioSciences issued on next quarter's earnings? Coherus BioSciences updated its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $275.00M-, compared to the consensus revenue estimate of $266.16 million. What is Dennis M. Lanfear's approval rating as Coherus BioSciences' CEO? 21 employees have rated Coherus BioSciences Chief Executive Officer Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among the company's employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Coherus BioSciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX). What is Coherus BioSciences' stock symbol? Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS." Who are Coherus BioSciences' major shareholders? Coherus BioSciences' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (16.71%), State Street Corp (2.70%), Aristotle Capital Boston LLC (2.44%), Marshall Wace LLP (2.42%), C WorldWide Group Holding A S (2.39%) and Peregrine Capital Management LLC (1.78%). Insiders that own company stock include Dennis M Lanfear, James Healy, Jean-Frederic Viret, Mcdavid Stilwell, Vincent R Anicetti and Vladimir Vexler. View institutional ownership trends. How do I buy shares of Coherus BioSciences? Shares of CHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Coherus BioSciences' stock price today? One share of CHRS stock can currently be purchased for approximately $4.46. How much money does Coherus BioSciences make? Coherus BioSciences (NASDAQ:CHRS) has a market capitalization of $421.34 million and generates $211.04 million in revenue each year. The biotechnology company earns $-291,750,000.00 in net income (profit) each year or ($3.32) on an earnings per share basis. How many employees does Coherus BioSciences have? The company employs 294 workers across the globe. Does Coherus BioSciences have any subsidiaries? The following companies are subsidiares of Coherus BioSciences: Coherus Intermediate Corp, InteKrin, InteKrin Russia, and InteKrin Therapeutics Inc..Read More How can I contact Coherus BioSciences? Coherus BioSciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The official website for the company is www.coherus.com. The biotechnology company can be reached via phone at (650) 649-3530 or via email at darrington@coherus.com. This page (NASDAQ:CHRS) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coherus BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.